03 March 2016

Two UK Biotechs Give Birth to Immuno-Oncology Startup Avvinity

Startup Avvinity Therapeutics has sprung up from the marriage of Horizon Discovery and Centauri Therapeutics to carve out a share of the $35 billion immune-oncology market, Horizon announced Wednesday. Avvinity will combine Horizon’s gene editing, immunology, oncology and drug discovery capabilities with Centauri’s Alphamer technology to “provide a powerful and proprietary platform to discover and develop novel immuno-oncology therapeutics, for both solid tumors and leukemias.” Source: Biospace 3/3/2016

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).